SEC Form 4 · accession 0001144204-15-051169
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yoram Bibring
Officer — Chief Financial Officer
Period of report
Aug 20, 2015
Accepted (ET)
Aug 21, 2015 · 9:00 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 20, 2015 | P | 8,500 | $3.04 | A | 50,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.0455, inclusive. The reporting person undertakes to provide to Brainstorm Cell Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.